Prominent Melbourne retinal disease researcher Professor Robyn Guymer is encouraged by the Phase 3 results of a trial she’s been involved in, investigating a new therapy she says is the only intervention shown to significantly slow the growth of lesions in dry AMD. Read more
A breakthrough bionic eye that delivers high-fidelity visual and spatial perception for blind people is one of 22 industry-led collaborative R&D projects to share in $47.1 million from the Federal Government. Read more
In 2020, ophthalmology became the first medical field in Australia to secure approval for a gene therapy. The one-off treatment can restore vision in people once resigned to a lifetime of blindness and is expected to pave the way for many more. MYLES HUME analyses the opportunities and challenges posed by ocular gene therapies. Read more
A major Sydney eye clinic that sees 130 patients a day has gone paperless and completely digitised the way it handles ophthalmic data. It’s created efficiencies that allow specialists to spend more time with patients.
New income data from the Australian Tax Office (ATO) has revealed ophthalmologists are the second highest paid medical specialty – second only to neurosurgeons – earning more than half a million dollars on average. Read more
A second National Eye Health Survey has been announced – this time with an added ear health component – and will examine close to 5,000 Aboriginal and Torres Strait Islander peoples and non-Aboriginal Australians over two years. Read more
A Hong Kong study highlighting a significant decrease in the time schoolchildren have been able to spend outdoors and a sharp increase in screen time is the latest to join mounting evidence that a rise in childhood myopia may be linked to the coronavirus pandemic. Read more
Nerve fibre loss and an increase in key immune cells on the cornea may be an identifying feature of ‘long COVID’, suggests a small study published in the British Journal of Ophthalmology. Read more
A leading researcher in Queensland has lauded the efficacy of a pioneering treatment for ocular neovascular disease recently trialled in animals.
Australasian drug company AFT Pharmaceuticals has announced results from a post-market study of licensed dry eye therapy NovaTears + Omega-3, stating it is a significantly effective treatment for the evaporative form of the disease. Read more